null
ChEBI ID: 50334
| Member | Definition | Role |
|---|---|---|
| 1-methyl-4-phenylpyridinium | A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position. | N-methyl-4-phenylpyridinium |
| 2-(dimethylaminostyryl)-1-ethylpyridinium | 2-(4-dimethylaminostyryl)-1-ethylpyridinium | |
| 4-(4-dihexadecylaminostyryl)-n-methylpyridium | A pyridinium cation with a methyl substituent at the 1-position and a 4-(dihexadecylamino)styryl substituent at the 4-position. | 4-(4-dihexadecylaminostyryl)-N-methylpyridium |
| 4-(4-dimethylaminostyryl)-1-methylpyridinium | A pyridinium cation obtained by methylation at position 1 of 4-(4-dimethylaminostyryl)pyridine | 4-[4-(dimethylamino)styryl]-N-methylpyridinium |
| amprolium | A pyridinium ion that is the cationic portion of amprolium, a veterinary drug which is used for prevention of coccidiosis in poultry and cattle. | amprolium(1+) |
| cetylpyridinium | cetylpyridinium | |
| dipyrithione | dipyrithione | |
| distigmine | A carbamate ester resulting from the formal condensation of both carboxy groups of hexane-1,6-diylbis(methylcarbamic acid) with the hydroxy group of 3-hydroxy-1-methylpyridinium. | distigmine |
| duodote | A pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2. | pralidoxime |
| isodesmosine | A pyridinium ion obtained by formal condensation of four molecules of lysine. | isodesmosine |
| n(1)-methylnicotinamide | A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent. | 1-methylnicotinamide |
| pralidoxime | A pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2. | pralidoxime |
| pyridostigmine | Pyridostigmine |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 897 (21.51) | 18.7374 |
| 1990's | 802 (19.23) | 18.2507 |
| 2000's | 1,057 (25.34) | 29.6817 |
| 2010's | 1,116 (26.76) | 24.3611 |
| 2020's | 299 (7.17) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 219 (4.98%) | 5.53% |
| Reviews | 128 (2.91%) | 6.00% |
| Case Studies | 117 (2.66%) | 4.05% |
| Observational | 2 (0.05%) | 0.25% |
| Other | 3,936 (89.41%) | 84.16% |